CDK 4/6 inhibitors combined with radiotherapy: A review of literature

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) namely palbociclib, ribociclib and abemaciclib were granted approval by the European Medicines Agency (EMA) between 2017 and 2018. They are currently prescribed in combination with hormone therapy to treat hormone receptor positive, HER2 negative...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Radiat Oncol
Main Authors: Bosacki, Claire, Bouleftour, Wafa, Sotton, Sandrine, Vallard, Alexis, Daguenet, Elisabeth, Ouaz, Hamza, Cojoracu, Iohel, Moslemi, Dariush, Molekzadehmoghani, Mona, Magné, Nicolas
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724290/
https://ncbi.nlm.nih.gov/pubmed/33319074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctro.2020.11.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados